Uric acid & coronary artery disease | CIA - Dove Medical Press
Introduction Coronary artery disease (CAD) remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Despite the identification of modifiable risk factors and the development of risk prediction models that enable recognition of individuals at greater risk of future events, CAD risk evaluation still lacks accuracy in daily clinical practice. 1,2 In this regard, investigating novel risk factors is of great clinical importance in improving CAD risk prediction, thus leading to better patient care. Uric acid is the metabolic end product of purine metabolism in humans, which is under the control of the enzyme xanthine oxidase. 3 Although a wealth of research has reported that greater serum uric acid (SUA) levels are associated with poorer survival in patients with CAD, 4–7 several recent studies have failed to establish such an association. 8,9 Apart from the differences in study design, clinical backgrounds, adjustment of confounders, length of follow-